Sunil Kumar
Sunil Kumar Buridipad, Hyderabad IN
Patent application number | Description | Published |
---|---|---|
20100048899 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM - The present invention relates to an improved process for preparing Rosuvastatin calcium of Formula I. | 02-25-2010 |
Sunil Kumar Buridipadu, Andhra Pradesh IN
Patent application number | Description | Published |
---|---|---|
20100029940 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM - The present invention relates to an improved process for preparing (2E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-propenal of Formula I which is an intermediate useful in the preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] calcium salt of Formula II | 02-04-2010 |
Sunil Kumar Buridipadu, Hyderabad IN
Patent application number | Description | Published |
---|---|---|
20090312547 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION - The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula (I). | 12-17-2009 |
Sunil Kumar Chandrashekharachar Suvarneshwar, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20110305239 | SELECTION OF MULTICAST ROUTER INTERFACES IN AN L2 SWITCH CONNECTING END HOSTS AND ROUTERS, WHICH IS RUNNING IGMP AND PIM SNOOPING - Multicast traffic received by a subnet that uses IGMP/PIM snooping may be efficiently processed so that only required multicast router interfaces are used. A router may, for example, receive a source-specific PIM join/prune message indicating that a multicast receiver of the multicast traffic is to join/leave a multicast group to receive/stop traffic from a multicast source; determine whether the router is a first hop router relative to a subnet of the multicast source; and forward, when the router is a first hop router relative to the subnet of the multicast source and is a non-designated router, the source-specific PIM join/prune message towards the subnet. | 12-15-2011 |
20140269707 | SELECTION OF MULTICAST ROUTER INTERFACES IN AN L2 SWITCH CONNECTING END HOSTS AND ROUTERS, WHICH IS RUNNING IGMP AND PIM SNOOPING - Multicast traffic received by a subnet that uses IGMP/PIM snooping may be efficiently processed so that only required multicast router interfaces are used. A router may, for example, receive a source-specific PIM join/prune message indicating that a multicast receiver of the multicast traffic is to join/leave a multicast group to receive/stop traffic from a multicast source; determine whether the router is a first hop router relative to a subnet of the multicast source; and forward, when the router is a first hop router relative to the subnet of the multicast source and is a non-designated router, the source-specific PIM join/prune message towards the subnet. | 09-18-2014 |
Sunil Kumar Chintakindi, Naperville, IL US
Patent application number | Description | Published |
---|---|---|
20150308836 | Dynamic Traffic Rendering - An initial geometry including one dimensional representation of a path is accessed. The initial geometry may be based traffic data. An envelope size is identified based on the path. The envelope size may be derived from a width, functional classification, or lane quantity associated with the path. A processor calculates a supplemental geometry based on the envelope size for the path and generates a two dimensional representation of the path based on the initial geometry, the supplemental geometry, and the envelope size. | 10-29-2015 |
20160091321 | Transmitting Map Data Images in a Limited Bandwidth Environment - Systems, methods, and apparatuses are provided for transmitting map data images in a limited bandwidth environment. In one embodiment, the method comprises determining or predicting, using a processor, a traffic condition or a weather condition for a location. The method further comprises developing at least one map image depicting the traffic condition or weather condition. The method further comprises encoding the map image in at least one payload. The method further comprises transmitting the at least one payload over-the-air to a navigation device. | 03-31-2016 |
Sunil Kumar Chintakindi, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20150285655 | Storing and Accessing Traffic Data Images in a Limited Bandwidth Environment - Systems, methods, and apparatuses are provided for storing and accessing traffic data images in a limited bandwidth environment. A traffic map image database is stored in a navigation device, where the database includes a plurality of traffic map images. A traffic condition is determined for a location of the navigation device. A traffic map image is retrieved from the database using a processor, where the traffic map image reflects the traffic condition for the location of the navigation device. The traffic map image is displayed on the navigation device. | 10-08-2015 |
Sunil Kumar C.r., Bangalore IN
Patent application number | Description | Published |
---|---|---|
20160091941 | Adapting Operating Parameters Of An Input/Output (IO) Interface Circuit Of A Processor - In an embodiment, processor includes at least one logic circuit to generate information to be output from the processor; an input/output (IO) interface circuit coupled to the at least one logic circuit to receive and transmit the information; a voltage regulator to provide an operating voltage to the IO interface circuit; and a controller to control the voltage regulator to provide the operating voltage at an adjusted level from a nominal operating voltage based on a process variation of at least a portion of a die including the IO interface circuit. Other embodiments are described and claimed. | 03-31-2016 |
Sunil Kumar C R, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20150186091 | DISPLAY DRIVER CAPABLE OF DRIVING MULTIPLE DISPLAY INTERFACES - A semiconductor chip is described. The semiconductor chip includes a display controller having a driver. The display controller is configurable to select a first, a second, a third and a fourth different display interface. The driver is designed to drive respective signals for each of the first, second, third and fourth interfaces through a single output. | 07-02-2015 |
Sunil Kumar Dhuper, Old Westbury, NY US
Patent application number | Description | Published |
---|---|---|
20090126723 | PATIENT INTERFACE MEMBER FOR USE IN AN AEROSOL INHALATION SYSTEM - A device for use in an aerosol inhalation system for delivering aerosolized medication includes a means for generating aerosolized medication and a housing that is operatively connected to the means for generating aerosolized medication such that the aerosolized medication is delivered to the housing. The device also includes a patient interface member removably connected to the housing and being separate therefrom. The patient interface member is for placement about a face of the patient and in communication with a mouth of the patient for delivering the aerosolized medication. The patient interface member incorporates a first flow control means that is positionable between an open position where aerosolized medication flows into an interior of the patient interface member when the patient inhales and a closed position when the patient exhales. The exhaled gas is vented from the interior through at least one vent port that is part of the patient interface member. | 05-21-2009 |
20110120457 | ADAPTER FOR USE IN AN AEROSOL DELIVERY SYSTEM - According to one aspect of the present invention, an aerosol inhalation system includes a first conduit member for delivering medication in the form of aerosol particles to a patient. The system includes a first holding chamber for holding the aerosol particles prior to deliver to the first conduit member and a valve mechanism associated with the first conduit member. The system also includes a first device in fluid communication with the first holding chamber for producing the aerosol particles and being sealingly yet releasably received within an adapter that forms an entrance into the first holding chamber. The adapter has a compressible material disposed thereon which is at least partially compressed by insertion of the first device to form the seal between the first device and the adapter. The aerosol inhalation apparatus is a closed system and is therefore capable of delivering a fixed concentration of the medication to the patient due to a valve of the valve mechanism being closed when the patient inhales and the medication is delivered to the patient. | 05-26-2011 |
20130081609 | MODULAR FIRE PIT TABLE - In one embodiment, a fire pit table apparatus includes a base having a ground contacting portion. The apparatus also includes a table assembly coupled to the base. The table assembly includes a table top for placement of one or more objects. The table top has an opening formed therein. The apparatus also includes a fire bowl assembly that is disposed within the opening of the table top such that the table top surrounds at least a portion of the fire bowl assembly and provides access to the fire bowl assembly. The fire bowl assembly includes a fire bowl and a hot top member that is disposed around the fire bowl. The hot top member includes a planar surface on which one or more objects can be placed, wherein the fire bowl and the hot top member are rotatably coupled to the table assembly to permit rotation of the fire bowl assembly relative to the table assembly. | 04-04-2013 |
20130199520 | MODULAR PULMONARY TREATMENT SYSTEM - A patient interface system for delivering a gas to a patient includes a patient interface device that includes at least one inhalation valve and at least one exhalation valve. The system also includes a venturi device that has at least one port for connection to a gas source. The venturi device has at least one primary air entrainment window and at least one secondary air entrainment window which is downstream of the at least one primary air entrainment window. The inhalation valve is disposed between: (1) the main body and (2) the primary and secondary air entrainment windows of the venturi device. At least one of the primary air entrainment window and secondary air entrainment window includes a means for closing the respective window, thereby changing a degree at which the respective window is open and changing a flow rate of the air flowing through the respective window. | 08-08-2013 |
20130199535 | GAS DELIVERY VENTURI - A venturi connector includes a housing having a mixing chamber defined therein and at least one window that is in fluid communication with the mixing chamber and is open to atmosphere to allow air to be entrained into the mixing chamber. The connector includes a nozzle actuator member includes a body having a plurality of discrete nozzles formed therein. The nozzles are defined by different sized venturi orifices through which gas flows, thereby allowing the concentration of the gas delivered to the patient to be varied. The nozzle actuator member is disposed within one window formed in the housing between the gas port and the mixing chamber such that the position of the nozzle actuator member within the housing can be adjusted so as to position one of the discrete nozzles into the gas flow path, thereby controlling the flow rate of the gas into the mixing chamber and ultimately the concentration of gas delivered to the patient. | 08-08-2013 |
Sunil Kumar Gandavadi, Hyderabad IN
Patent application number | Description | Published |
---|---|---|
20130281663 | PREPARATION OF POLYPEPTIDES AND SALTS THEREOF - The application relates to processes for preparing polypeptides. Also provided are processes for preparing glatiramer acetate. | 10-24-2013 |
Sunil Kumar Garg, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20160110836 | Arranging on-demand services based on one or more predefined rules - A transport request for a transport service for a user can be received from a user device. Based, at least in part, on information from the transport request, a computing system can determine that the transport request is subject to one or more rules stored in a rules database accessible by the computing system. In response to determining that the transport request is subject to one or more rules, the computing system can determine whether the transport request is valid based, at least in part, on the one or more rules and information from the transport request. In response to determining that the transport request is valid, the transport request can be processed to select a driver to provide the transport service for the user. In addition, the cost for the transport service can be paid by an entity other than the user. | 04-21-2016 |
Sunil Kumar Kandukuri Narayan, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090247164 | HANDOFF ALGORITHM AND ARCHITECTURE FOR MOBILE SYSTEM - A reference signal and handoff management (RSHM) program executing on a mobile device detects reference signals, allocates them into groups, and performs handoffs between synchronous and asynchronous sectors. Sectors are allocated to an active group. Sectors from the active group that satisfy a channel quality constraint are allocated to a second group. Sectors from the second group that satisfy a link budget constraint are allocated to a third group. The RSHM program calculates a weighted characteristic of the forward and reverse links of sectors in the third group. The RSHM program performs handoffs from current serving sectors to sectors having the largest weighted characteristic that exceeds the weighted characteristic of the current serving sector by an hysteresis amount. Battery power of the mobile device is efficiently used to perform handoffs and to manage reference signals in heterogeneous network environments by preventing unnecessary handoffs, overhead downloads, access probes and new registrations. | 10-01-2009 |
20150049793 | INTERFACE SHARING BETWEEN DIGITAL AND RADIO FREQUENCY CIRCUITS - Exemplary embodiments are related to interfacing a digital module and a radio-frequency (RF) module of a wireless communication device. A device may include a digital module configured to output at least one constant-envelope phase modulated signal. The device may further include an RF module configured to receive the at least one constant-envelope phase modulated signal and generate one or more digital bits in response to receipt of the at least one constant-envelope phase modulated signal. | 02-19-2015 |
Sunil Kumar Kandukuri Narayana, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20110149943 | TIME TRACKING LOOPS FOR A COMMUNICATION SYSTEM UTILIZING A CYCLIC PREFIX - Techniques for performing time tracking in a communication system utilizing a cyclic prefix are described. In an aspect, a receiver may detect for large timing errors based on early and late received samples obtained with early and late FFT windows, respectively. The receiver may derive first and second channel impulse response (CIR) estimates based on the early and late received samples, respectively, determine an early channel energy based on the first CIR estimate, determine a late channel energy based on the second CIR estimate, compute an update amount based on the early and late channel energies, and update the FFT window position based on the update amount. In another aspect, the receiver may perform time tracking with an inner time tracking loop (TTL) and an outer TTL. The receiver may update the FFT window position in coarse steps with the outer TTL and in fine steps with the inner TTL. | 06-23-2011 |
20110158367 | DUAL FREQUENCY TRACKING LOOP FOR OFDMA SYSTEMS - Methods and apparatus for correcting frequency errors between a carrier frequency of a signal received by a wireless device and a reference frequency local to the device. For certain aspects, such a method generally includes receiving a signal in a receiver having an LO producing a reference frequency, a radio frequency (RF) phase-locked loop (PLL), and a digital rotator, estimating a frequency difference between a carrier frequency of the received signal and the LO reference frequency, and applying the estimated frequency difference to the RF PLL and the digital rotator. | 06-30-2011 |
Sunil Kumar Kc, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20110034441 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF - Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. | 02-10-2011 |
20110034497 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 02-10-2011 |
20110190290 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 08-04-2011 |
20120046320 | BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS - The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases. | 02-23-2012 |
20130040976 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 02-14-2013 |
20130079329 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS - Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-28-2013 |
20130225576 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 08-29-2013 |
20130267495 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 10-10-2013 |
20130296302 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases. | 11-07-2013 |
20130296307 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 11-07-2013 |
20130296341 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 11-07-2013 |
20140005170 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | 01-02-2014 |
20140005206 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | 01-02-2014 |
20140005228 | B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS | 01-02-2014 |
20140005383 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | 01-02-2014 |
20140045815 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS - Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 02-13-2014 |
20140080902 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS - The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases. | 03-20-2014 |
20140179696 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 06-26-2014 |
20140194441 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 07-10-2014 |
20140243349 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS - The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases. | 08-28-2014 |
20140323479 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 10-30-2014 |
20150045360 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 02-12-2015 |
20150045379 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 02-12-2015 |
20150072981 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases. | 03-12-2015 |
20150150862 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases. | 06-04-2015 |
20150152105 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 06-04-2015 |
20150266825 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A. | 09-24-2015 |
20150299157 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS - The present application discloses a compound which is | 10-22-2015 |
20150299174 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS - The present application discloses a compound which is | 10-22-2015 |
20160068529 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-10-2016 |
20160068547 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-10-2016 |
20160068548 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-10-2016 |
20160068549 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-10-2016 |
20160068550 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-10-2016 |
20160068551 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-10-2016 |
20160075701 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-17-2016 |
20160090380 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 03-31-2016 |
20160101092 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 04-14-2016 |
Sunil Kumar Neckaraje, Hyderabad IN
Patent application number | Description | Published |
---|---|---|
20150242455 | SYSTEMS AND METHODS FOR SECURITY PANEL CONTENT MANAGEMENT - A system for security panel content management is disclosed. A security panel can request and receive text files with content information from a content management server. The security panel can parse the text files and use the content information to populate a content store. The content store can display the content information for a security panel user, and the security panel can retrieve content from a remote file server based on a user request via the content store. | 08-27-2015 |
Sunil Kumar Neckaraje, Karnataka IN
Patent application number | Description | Published |
---|---|---|
20090204814 | Method and apparatus for communicating information between a security panel and a security server - A security panel includes a processor, memory, and a network interface having a unique MAC address, and is configured to communicate over a network with a server. A method for registering the security panel with the server includes contacting the server utilizing a network address stored in the memory. A dealer ID, a line number, and a unique account number is sent to the server. The dealer ID, the line number, and the unique account number are stored in the memory. An encryption key is received for encryption of additional communication between the security panel and the server. The unique MAC address is sent to the server in an encrypted session to verify the security panel to the server. | 08-13-2009 |
20120096265 | Method and apparatus for communicating information between a security panel and a security server - A security panel includes a processor, memory, and a network interface having a unique MAC address, and is configured to communicate over a network with a server. A method for registering the security panel with the server includes contacting the server utilizing a network address stored in the memory. A dealer ID, a line number, and a unique account number is sent to the server. The dealer ID, the line number, and the unique account number are stored in the memory. An encryption key is received for encryption of additional communication between the security panel and the server. The unique MAC address is sent to the server in an encrypted session to verify the security panel to the server. | 04-19-2012 |
Sunil Kumar Rajgopal, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090295660 | Non-Planar Metamaterial Antenna Structures - Antennas for wireless communications based on metamaterial (MTM) structures to arrange one or more antenna sections of an MTM antenna away from one or more other antenna sections of the same MTM antenna so that the antenna sections of the MTM antenna are spatially distributed in a non-planar configuration to provide a compact structure adapted to fit to an allocated space or volume of a wireless communication device, such as a portable wireless communication device. | 12-03-2009 |
20110267244 | MULTI-FUNCTIONAL CRLH ANTENNA DEVICE - This application relates to a multi-functional Composite Right and Left Handed CRLH antenna device. A conductive element of a wireless device is incorporated into the antenna structure for reuse. In one embodiment a peripheral feature, such as a key dome, is incorporated into the antenna device. In this way, the antenna structure includes portions which are multi-functional. | 11-03-2011 |
20120001826 | ENHANCED METAMATERIAL ANTENNA STRUCTURES - A wireless device having an antenna structure incorporates a conductive structure to extend an effective length of at least one component of the antenna structure. The enhanced 3-D conductive structure is applicable to a variety of antenna types, including, but not limited to, a CRLH structured antenna. | 01-05-2012 |
20130050029 | NON-PLANAR METAMATERIAL ANTENNA STRUCTURES - Antennas for wireless communications based on metamaterial (MTM) structures to arrange one or more antenna sections of an MTM antenna away from one or more other antenna sections of the same MTM antenna so that the antenna sections of the MTM antenna are spatially distributed in a non-planar configuration to provide a compact structure adapted to fit to an allocated space or volume of a wireless communication device, such as a portable wireless communication device. | 02-28-2013 |
20150102968 | ANTENNA DEVICES HAVING FREQUENCY-DEPENDENT CONNECTION TO ELECTRICAL GROUND - Antenna devices and techniques that provide specific control of the spatial distributions of DC and RF signals at various positions in a wireless apparatus are disclosed. The wireless apparatus includes various device components each having specifications for achieving desired operations in antenna devices. | 04-16-2015 |
Sunil Kumar Singh, Mirzapur (up) IN
Patent application number | Description | Published |
---|---|---|
20140315382 | Interconnection Wires of Semiconductor Devices - A method of forming a semiconductor device includes forming a plurality of substantially equal-spaced first spacers having a first pitch over a substrate and forming first metal interconnecting wires utilizing the first spacers. The method also includes forming a plurality of substantially equal-spaced second spacers in such a way to abut, respectively, the plurality of first metal interconnecting wires and define a plurality of substantially equal-spaced trenches. A plurality of second metal interconnecting wires are disposed, respectively, within the trenches and the second spacers are removed, thereby defining a plurality of substantially equal-spaced channels. | 10-23-2014 |
Sunil Kumar Singh, Hsinchu TW
Patent application number | Description | Published |
---|---|---|
20130334700 | ETCH DAMAGE AND ESL FREE DUAL DAMASCENE METAL INTERCONNECT - A method of forming a dual damascene metal interconnect for a semiconductor device. The method includes forming a layer of low-k dielectric, forming vias through the low-k dielectric layer, depositing a sacrificial layer, forming trenches through the sacrificial layer, filling the vias and trenches with metal, removing the sacrificial layer, then depositing an extremely low-k dielectric layer to fill between the trenches. The method allows the formation of an extremely low-k dielectric layer for the second level of the dual damascene structure while avoiding damage to that layer by such processes as trench etching and trench metal deposition. The method has the additional advantage of avoiding an etch stop layer between the via level dielectric and the trench level dielectric. | 12-19-2013 |
20140117561 | ETCH DAMAGE AND ESL FREE DUAL DAMASCENE METAL INTERCONNECT - A method of forming a dual damascene metal interconnect for a semiconductor device. The method includes forming a layer of low-k dielectric, forming vias through the low-k dielectric layer, depositing a sacrificial layer, forming trenches through the sacrificial layer, filling the vias and trenches with metal, removing the sacrificial layer, then depositing an extremely low-k dielectric layer to fill between the trenches. The method allows the formation of an extremely low-k dielectric layer for the second level of the dual damascene structure while avoiding damage to that layer by such processes as trench etching and trench metal deposition. The method has the additional advantage of avoiding an etch stop layer between the via level dielectric and the trench level dielectric. | 05-01-2014 |
20140175650 | INTERCONNECTION WIRES OF SEMICONDUCTOR DEVICES - Disclosed are a method to fabricate interconnection wires of a semiconductor device in a way to utilize benefits of copper interconnection and low k dielectric insulation while avoiding the problem of low k damage due to etching processes, and so fabricated interconnection wires. The method saves fabrication time and cost by reduced number of steps and also resolves metal gap fill issue. The method may comprise providing layers of a substrate, an etch stop layer and a sacrificial layer, forming first spacers, forming first copper interconnecting wires, removing the first spacers; forming polymer-like second spacers by depositing plasma gases in an etching chamber, forming second metal interconnecting wires, removing the second spacers to define channels interwoven with alternating first and second metal interconnecting wires, forming an anti-diffusion barrier around each of the first and second metal interconnecting wires, and filling the channels with a dielectric material for insulation. | 06-26-2014 |
20140187044 | ADDITION OF CARBOXYL GROUPS PLASMA DURING ETCHING FOR INTERCONNECT RELIABILITY ENHANCEMENT - The present disclosure is directed to a method of manufacturing a semiconductor structure in which a low-k dielectric layer is formed over a semiconductor substrate. Features can be formed proximate to the low-k dielectric layer by plasma etching with a plasma formed of a mixture of a CO | 07-03-2014 |
Sunil Kumar Singh, Hsin-Chu TW
Patent application number | Description | Published |
---|---|---|
20090091038 | AIR GAP FOR INTERCONNECT APPLICATION - The present disclosure provides a method for fabricating an integrated circuit. The method includes forming an energy removable film (ERF) on a substrate; forming a first dielectric layer on the ERF; patterning the ERF and first dielectric layer to form a trench in the ERF and the first dielectric layer; filling a conductive material in the trench; forming a ceiling layer on the first dielectric layer and conductive material filled in the trench; and applying energy to the ERF to form air gaps in the ERF after the forming of the ceiling layer. | 04-09-2009 |
Sunil Kumar Swamy Rajan, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20130071435 | NOVEL HERBAL FORMULATION FOR THE MODULATION OF IMMUNE SYSTEM OF HIV INFECTED PATIENTS AND A PROCESS OF PREPARATION THEREOF - An herbal formulation for the modulation of immune system of HIV infected patients and a process of preparation thereof are provided. The process includes (i) preparing a hydromethanolic extract of at least one plant selected from Hippophae rhamnoides, | 03-21-2013 |
Sunil Kumar Veluvali, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20150180844 | LOW LATENCY AUTHENTICATION OF GATED MEDIA RELAY SERVICES - Media relay services are often used to establish sufficiently direct connections in order to enable provisioning of a real-time media service and/or improve the quality of real-time media services. However, media relay services are often gated using authentication systems that add undesirable delay to the delivery and/or access to a real-time media service, which in turn diminish the user experience. By contrast, various implementations disclosed herein include apparatuses, systems, and methods of providing low latency authentication of gated media relay services. For example, in some implementations, a method includes receiving a request for access to a gated media relay service, providing provisional access to the service until an authentication result is available, determining whether the requesting device is authorized to access the media relay service, and at least one of ending or continuing access to the media relay service based on the authentication result. | 06-25-2015 |